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BACKGROUND. Few studies have examined the outcomes for Hispanic men with
prostate carcinoma and incorporated socioeconomic factors in association with
race/ethnicity in affecting survival, adjusting for factors on cancer stage, grade,
comorbidity, and treatment.

METHODS. We studied a population-based cohort of 61,228 men diagnosed with
local or regional stage prostate carcinoma at age 65 years or older between 1992
and 1999 in the 11 SEER (Surveillance, Epidemiology, and End Results) areas,
identiﬁed from the SEER-Medicare linked data with up to 11 years of followup.
RESULTS. Low socioeconomic status was signiﬁcantly associated with decreasing
survival in all men with prostate carcinoma. Those living in the community with
the lowest quartile of socioeconomic status were 31% more likely to die than those
living in the highest quartile (hazard ratio [HR] of all-cause mortality: 1.31; 95%
conﬁdence interval [CI]: 1.25–1.36) after adjustment for patient age, comorbidity,
Gleason score, and treatment. The HR remained almost unchanged after controlling for race/ethnicity (HR: 1.32; 95% CI: 1.26 –1.38). Compared with Caucasians,
the risk of mortality in African American men was marginally signiﬁcantly higher
(HR: 1.06; 95% CI: 1.01–1.11) after controlling for education, and no longer significant after adjusting for poverty, income, or composite socioeconomic variable; the
HR was lower for Hispanic men (HR: 0.80; 95% CI: 0.72– 0.89) after adjustment for
education and other socioeconomic variables.
CONCLUSION. Racial disparity in survival among men with local or regional prostate
carcinoma was largely explained by socioeconomic status and other factors. Lower
socioeconomic status appeared to be one of the major barriers to achieving
comparable outcomes for men with prostate carcinoma. Cancer 2006;106:
1276 – 85. © 2006 American Cancer Society.

KEYWORDS: prostate carcinoma, race/ethnicity, disparity, socioeconomic status,
survival.

T

here are remarkable worldwide variations in the incidence of
prostate carcinoma, with the highest age-standardized incidence
rate in the US.1 In the US, prostate carcinoma is currently the most
commonly diagnosed cancer in men, and incidence and mortality
varies greatly by race/ethnicity.2– 6 Previous studies have shown that
the increased mortality in African American patients with prostate
carcinoma can be attributed to more aggressive cancers and more
advanced stage-at-diagnosis,7–9 differences in treatment,10 –19 socioeconomic factors,20 –23 and physician characteristics.24 For example,
results from the Prostate Cancer Outcomes Study demonstrated that
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African Americans with more aggressive prostate carcinoma were less likely to undergo radical prostatectomy and more likely to be treated conservatively than
Caucasians.13 However, few studies have examined
the outcomes in Hispanic men and incorporated socioeconomic factors in association with race/ethnicity
and determined their impact on the survival of men
with prostate carcinoma, in addition to factors on
cancer stage, grade, comorbidity, and treatment. A
large cohort of men diagnosed with local/regional
stage prostate carcinoma at age 65 or older, identiﬁed
from the nationwide, population-based Surveillance,
Epidemiology, and End Results (SEER) cancer registries–Medicare linked databases with up to 11 years of
followup, were studied to examine the effect of race/
ethnicity and socioeconomic factors on long-term survival. These linked data not only provided accurate
information on tumor stage and grade (Gleason score)
at diagnosis and long-term followup of the vital status,
but also allowed the examination of various socioeconomic factors at the level of census tract and zip
codes. In addition, comorbid conditions and the type
of treatment (chemotherapy and hormonal therapy)
could be uniquely identiﬁed from Medicare claims
data. We hypothesized that there were no racial and
ethnic differences in long-term survival of prostate
carcinoma patients after controlling for differences in
age, tumor Gleason score, comorbidity, treatment,
and socioeconomic status.

MATERIALS AND METHODS
Data Sources
The SEER program, supported by the National Cancer
Institute (NCI), includes population-based tumor registries in 11 selected geographic areas3,4,25,26: the metropolitan areas of San Francisco/Oakland, Detroit, Atlanta, and Seattle; Los Angeles county; the San Jose–
Monterey area; and the states of Connecticut, Iowa,
New Mexico, Utah, and Hawaii, covering ⬎ 14% of the
US population. The registries ascertain all newly diagnosed (incident) prostate carcinoma cases from multiple reporting sources such as hospitals, outpatient
clinics, and laboratories.
The Medicare program provides payments for
hospital, physician, and outpatient medical services
for ⬎ 97% of persons age ⱖ 65.27,28 Cases reported by
the SEER cancer registries from 1973–1999 were
matched against the Medicare master enrollment ﬁles.
Medicare claims data are available through 2002. For
persons age ⱖ 65 appearing in the SEER records,
Medicare eligibility could be identiﬁed for 94% of
these cases. The method of linking these data has been
described elsewhere.25,26 The Committee for Protection of Human Subjects at the University of Texas
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Health Science Center at Houston approved this
study.

Study Population
Our study is based on the analytical SEER-Medicare
ﬁles that excluded men who did not have full coverage
of both Medicare Parts A and B, and were members of
Health Maintenance Organizations (HMOs) to ensure
the completeness of Medicare claims. The study population consisted of 61,228 men diagnosed with local/
regional stage prostate carcinoma at age ⱖ 65 between
1992 and 1999 from the 11 SEER areas. Because local
and regional diseases were combined as a single category in SEER data, we were unable to further stratify
the analysis by local versus regional stage. However,
we used the American Joint Committee on Cancer
(AJCC) stage available in SEER to control for residual
confounding, although 37% of cases had missing information. Of the 61,228 men, 53,764 were Caucasians
(non-Hispanic whites), 6,321 African Americans (nonHispanic blacks), and 1,143 Hispanics.

Study Variables
Outcome variables
The survival time in months was calculated from the
date of diagnosis to the date of death or to the date of
last followup (December 31, 2002). Because SEER reported only the month and year of diagnosis, we arbitrarily deﬁned the day of diagnosis as the 15th of the
month. All-cause mortality was deﬁned as death from
any cause that was the underlying cause of death,
which was identiﬁed by the SEER program through
linking the SEER data with the National Death Index
data from the National Center for Health Statistics.
Patients still alive at the last followup were censored.
Prostate carcinoma-speciﬁc mortality was deﬁned as
prostate carcinoma as the underlying cause of death.
In this speciﬁc analysis, patients who died of causes
other than prostate carcinoma or were still alive at the
last followup were censored.

Socioeconomic status
Three variables from the 1990 census available in the
SEER-Medicare linked data were used to deﬁne socioeconomic status: 1) education: percent of adults age
ⱖ 25 who had younger than 12 years of education at
the zip code level, which was categorized into quartiles: ﬁrst (⬍ 11.9%), second (11.9 –18.1%), third (18.2–
26.2%), and fourth quartile (⬎ 26.2%); 2) poverty:
percent of persons living below the poverty line at
the census tract level, which was categorized into
quartiles: ﬁrst (⬍ 3.6%), second (3.6 – 6.7%), third (6.8 –
12.6%), and fourth quartile (⬎ 12.6%); 3) income:
median annual household income at the zip code
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level, which was also categorized into quartiles: ﬁrst
(⬎ $43,875), second ($34,807– 43,875), third ($26,111–
34,806), and fourth quartile (⬍ $26,111). We used poverty at the census tract level because this variable is
not available at the zip code level. For elderly Medicare beneﬁciaries, poverty level could be the most
directly relevant proxy measure of their economic status.27
In addition to these socioeconomic variables, we
also created a composite variable that was generated
by combining these three variables based on the
methods of Robert et al.28
The above three socioeconomic variables were
ﬁrst recoded to ensure that lower values represent
higher socioeconomic status (income was made negative). We then converted these values into normal
scores. Finally, we summed the scores of these three
variables that were equally weighted and categorized
the total scores into quartiles. Those subjects with
missing information on socioeconomic status were
categorized separately.

Comorbidity index
Comorbidity was ascertained from Medicare claims by
identifying diagnoses or procedures performed between 1 year before and 1 month after the diagnosis of
prostate carcinoma. Details on creating a comorbidity
score have been previously reported.29,30

Treatment
Surgery and radiation therapy
Patients were deﬁned as having received radical prostatectomy if it was indicated in the SEER data (codes
40 –70)31 or if there was a Medicare claim for radical
prostatectomy (ICD-9 code32 of 605, or CPT codes33 of
55810 –55815 or 55840 –55845). Patients were deﬁned
as having received radiation therapy if either SEER or
Medicare claims so indicated.34

Hormonal therapy
Patients with prostate carcinoma were deﬁned as having received hormonal therapy (androgen deprivation
therapy) if any of the following Medicare procedure
codes indicated so within 6 months of the diagnosis33,35: the procedure codes for leuprolide (J1950 or
J9217–J9219) and for goserelin (J9202); or procedure
codes for orchiectomy (54520 –54521, 54530, or 54535).

Chemotherapy
The detailed methods for the identiﬁcation of chemotherapy use through Medicare claims have been previously described.36 In brief, patients with prostate
carcinoma were deﬁned as having received chemotherapy if any of the following Medicare procedure

codes so indicated within 6 months of diagnosis31–36:
the ICD-9-CM procedure code of 99.25 and V codes of
V58.1, V66.2, or V67.2; the procedure codes of 96400 –
96549, J8530 –J8999, J9000 –J9999 (except those codes
for hormonal therapy), Q0083–Q0085; or revenue center codes of 0331, 0332, and 0335.

Other Characteristics
Patient and tumor characteristics such as age at diagnosis (categorized as 65– 69, 70 –74, 75–79, 80 or older),
race/ethnicity (Caucasian, African American, and Hispanic), AJCC stage (I, II, III, IV, or unknown), grade
(Gleason score), year of diagnosis (1992–1999), and
geographic area (11 SEER areas) were available from
SEER.

Analysis
The differences in the distribution of baseline characteristics among the three racial/ethnic groups were
tested using the chi-square statistic. The Cox proportional hazard regression model was used for analysis
of survival using the PHREG procedure in the SAS
system (Cary, NC).37 The proportionality assumption
was satisﬁed when the log–log Kaplan–Meier curves
for survival functions by race/ethnicity or socioeconomic status were parallel and did not intersect.37,38
The interaction between race/ethnicity and socioeconomic status was tested using the product term of
these two variables in the model. Analyses were adjusted for age, tumor AJCC stage, Gleason score, treatment (surgery or radiation, chemotherapy, or hormonal therapy), comorbidity score, year of diagnosis,
and geographic area. A series of statistical models
were tested for the associations between survival and
socioeconomic status and race/ethnicity and are also
noted in the table footnotes.

RESULTS
Table 1 presents the distribution of patient age, tumor
characteristics, and type of treatment among three
racial/ethnic groups of patients diagnosed with local/
regional stage prostate carcinoma. A higher proportion of cases were diagnosed at age ⱖ 80 in Caucasian
men (16.3%) than in African Americans (13.5%),
whereas Hispanics had the highest percentage (36.0%)
of cases diagnosed at age 65– 69. A slightly greater
proportion of cases were diagnosed at a lower tumor
grade or lower Gleason score and had a lower comorbidity score in Caucasian and Hispanic men than that
in African Americans. Although signiﬁcant, the percentage of men receiving various treatments was relatively close among ethnic groups. For example, 23.9%
of African Americans received hormonal therapy compared with 27.0% of Caucasians and 28.7% of Hispan-
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TABLE 1
Comparison of Demographic and Tumor Characteristics and Type of
Treatment among Different Racial or Ethnic Groups in Men with
Locoregional Prostate Carcinoma
African
American

Caucasian
%

n

%

Hispanic

Characteristic

n

n

Median age, yrs (range)
Age, yrs
65–69
70–74
75–79
ⱖ 80
AJCC stage
I
II
III
IV
Unknown
Gleason score
2–4
5–7
8–10
Unknown
Comorbidity score
0
1
2
ⱖ3
Surgery and radiation
Radical prostatectomy
Radiation
Both
Neither
Chemotherapy
None
Yes
Hormonal therapy
None
Yes
Total

73 (65–103)

72 (65–103)

71 (65–101)

15,416
17,324
12,271
8753

28.7
32.2
22.8
16.3

2131
2023
1314
853

33.7
32.0
20.8
13.5

411
390
221
121

36.0
34.1
19.3
10.6

17,636
6701
7717
1733
19,977

32.8
12.5
14.4
3.2
37.2

2263
866
681
212
2299

35.8
13.7
10.8
3.4
36.4

387
147
173
48
388

33.9
12.9
15.1
4.2
34.0

7475
33,218
10,438
2633

13.9
61.8
19.4
4.9

740
3789
1410
382

11.7
59.9
22.3
6.0

198
650
240
55

17.3
56.9
21.0
4.8

34,402
12,565
4342
2455

64.0
23.4
8.1
4.6

3394
1611
747
569

53.7
25.5
11.8
9.0

669
290
96
88

58.5
25.4
8.4
7.7

12,907
20,536
1205
19,116

24.0
38.2
2.2
35.6

1070
2463
89
2699

16.9
39.0
1.4
42.7

328
327
26
462

28.7
28.6
2.3
40.4

44,219
9545

82.3
17.8

5345
976

84.6
15.4

861
282

75.3
24.7

39,266
14,498
53,764

73.0
27.0
100.0

4808
1513
6321

76.1
23.9
100.0

815
328
1143

71.3
28.7
100.0
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TABLE 2
Comparison of SES among Different Racial or Ethnic Groups in Men
with Prostate Carcinoma
SES
(quartile from high to
low)

African
American

Caucasian

Hispanic

n

%

n

%

n

%

14,437
14,059
13,034
9193
3041

26.9
26.2
24.2
17.1
5.7

237
472
1168
4260
184

3.8
7.5
18.5
67.4
2.9

60
122
225
666
70

5.3
10.7
19.7
58.3
6.1

14,861
14,429
13,974
9603
897

27.6
26.8
26.0
17.9
1.7

267
529
838
4639
48

4.2
8.4
13.3
73.4
0.8

69
132
208
693
41

6.0
11.6
18.2
60.6
3.6

14,033
13,593
12,772
10,325
3041

26.1
25.3
23.8
19.2
5.7

288
587
1438
3824
184

4.6
9.3
22.8
60.5
2.9

99
175
322
477
70

8.7
15.3
28.2
41.7
6.1

14,059
13,732
13,199
9128
3646
53,764

26.2
25.5
24.6
17.0
6.8
100.0

204
460
914
4528
215
6321

3.2
7.3
14.5
71.6
3.4
100.0

56
121
199
661
106
1143

4.9
10.6
17.4
57.8
9.3
100.0

%

AJCC: American Joint Commission on Cancer.

ics. Similarly, 42.7% of African Americans received
neither radical prostatectomy nor radiation compared
with 35.6% of Caucasians and 40.4% of Hispanics.
Table 2 presents the distribution of socioeconomic status among three racial/ethnic groups of patients. A large proportion of African American and
Hispanic men were in the poorest quartiles of education, poverty, income, and composite socioeconomic
status compared with that of Caucasians. For example,
73.4% of African Americans and 60.6% of Hispanics
were in the poorest quartile of socioeconomic status
as measured by the poverty level compared with
17.9% of Caucasians. The differences in the distribution of the above factors in Tables 1 and 2 between

Education
1st
2nd
3rd
4th
Missing
Poverty
1st
2nd
3rd
4th
Missing
Income
1st
2nd
3rd
4th
Missing
Composite SES
1st
2nd
3rd
4th
Missing
Total
SES: socioeconomic status.

Caucasians and African Americans or Hispanics were
all statistically signiﬁcant.
Table 3 presents the 3-, 5-, and 10-year survival by
racial/ethnic groups and socioeconomic status. Because the last date of followup in Medicare was December 2002, all cases in our study cohort had been
followed for at least 3 years. The 3-year survival from
all-causes was 91% in Hispanics, 87.8% in Caucasians,
and 84.1% in African Americans. Survival increased
with improving socioeconomic status. For example,
the 3-year survival was 84.5% in subjects who lived in
the community with lowest education level, and 90.6%
in those with highest quartile of education. The improvement in survival associated with higher socioeconomic status was consistent when using other
measures of socioeconomic status (poverty, income,
and composite socioeconomic status). This survival
pattern in association with race/ethnicity and socioeconomic status was similar at the 5- and 10-year level
and for prostate carcinoma speciﬁc survival (Table 3).
Table 4 presents the effect of socioeconomic factors on all-cause mortality and prostate carcinoma-
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TABLE 3
Survival in Men with Locoregional Prostate Carcinoma by Race or
Ethnicity and SES
3-yr survival (%) 5-yr survival (%)
(cases in 1992- (cases in 19921999)
1997)

10-yr survival
(%) (cases in
1992–1993)

Race or ethnicity and SES All
Disease- All
Disease- All
Disease(quartile from high to low) causes speciﬁc causes speciﬁc causes speciﬁc
Racial or ethnic group
Caucasian
African American
Hispanic
Education
1st
2nd
3rd
4th
Missing
Poverty
1st
2nd
3rd
4th
Missing
Income
1st
2nd
3rd
4th
Missing
Composite SES
1st
2nd
3rd
4th
Missing
Total

87.8
84.1
91.0

98.2
97.5
98.9

78.0
72.6
83.5

96.4
95.3
97.3

52.6
43.3
61.3

94.0
91.1
95.6

90.6
88.2
86.3
84.5
87.7

98.7
98.3
98.0
97.6
98.7

82.6
78.9
75.6
72.9
77.0

97.3
96.6
95.9
95.4
97.1

59.5
53.0
49.5
45.2
54.1

95.4
93.9
93.0
92.3
94.6

89.9
88.3
87.6
84.1
87.1

98.4
98.2
98.4
97.7
98.6

81.3
79.2
77.3
72.3
77.2

96.8
96.4
96.6
95.5
96.2

56.4
54.2
51.7
41.8
54.6

94.6
93.9
94.2
92.2
91.6

90.0
88.0
86.9
84.8
87.7

98.5
98.1
98.2
97.7
98.7

81.6
79.0
76.4
73.1
77.0

97.0
96.4
96.6
95.5
96.2

56.9
53.5
51.0
45.7
54.1

94.5
94.1
94.0
92.1
94.6

90.6
88.3
86.9
84.0
87.5
87.5

98.7
98.1
98.3
97.5
98.7
98.2

82.5
79.1
76.4
72.1
77.1
77.5

97.2
96.3
96.3
95.4
96.9
96.3

58.6
53.9
50.5
44.1
54.1
51.9

94.9
93.9
94.0
92.0
94.1
93.7

SES: socioeconomic status.

speciﬁc mortality while adjusting for race/ethnicity
and other factors. There was a clear pattern for the
increasing hazard ratio (HR) of mortality associated
with lower socioeconomic status. The magnitude and
trend in HRs were consistent regardless of which socioeconomic variables were used. For example, those
living in communities with the lowest composite socioeconomic level were 31% more likely to die from
all-causes than those living in the highest socioeconomic level communities (P ⬍ 0.001 for trend) (Model
1). The risk of all-cause mortality remained almost
unchanged after controlling for race/ethnicity (Model
2). Whereas the HR for prostate carcinoma-speciﬁc
mortality was reduced slightly after adjusting for race/
ethnicity, those living in communities with the lowest
socioeconomic status were still considerably more

likely to die than those living in communities with the
highest quartile (Model 4).
The effects of race/ethnicity on the risk for allcause mortality and prostate carcinoma-speciﬁc mortality are presented in four different statistical models
in Table 5. Compared with Caucasian men, African
Americans were 14% more likely to die and Hispanic
men were 15% less likely to die, after controlling for
other factors. When additionally controlled for composite socioeconomic status, the HR of all-cause mortality was no longer signiﬁcantly higher in African
Americans compared with Caucasians (HR: 1.01; 95%
conﬁdence interval [CI]: 0.96 –1.06), whereas Hispanic
men were still signiﬁcantly less likely to die than Caucasians (HR: 0.78; 95% CI: 0.70 – 0.87). When controlled for poverty or median income, there was no
signiﬁcant difference in all-cause mortality between
Caucasian and African American men. For example,
when controlled for income, the HR in African Americans was no longer signiﬁcantly higher (HR: 1.02; 95%
CI: 0.98 –1.08) compared with Caucasians, whereas
Hispanics still had a signiﬁcantly lower risk (HR: 0.79;
95% CI: 0.71– 0.88). Similarly, after adjusting for poverty, the HR was 1.04 (95% CI: 0.99 –1.09) for African
Americans and 0.80 (95% CI: 0.72– 0.89) for Hispanics
as compared with Caucasians. However, the HR was
substantially reduced but still marginally higher in
African American men after adjusting for education
(HR: 1.06; 95% CI: 1.01–1.11), whereas Hispanic men
were signiﬁcantly less likely to die than Caucasians
(HR: 0.80; 95% CI: 0.72– 0.89).
African American patients also had a higher but
insigniﬁcant risk of prostate carcinoma-speciﬁc mortality than Caucasians, whereas Hispanics had a lower
but insigniﬁcant risk of prostate carcinoma-speciﬁc
mortality after adjusting for composite socioeconomic
status in addition to other factors (Model 4). However,
the HRs of prostate carcinoma-speciﬁc mortality were
signiﬁcantly higher in African Americans after adjusting for education (HR: 1.20; 95% CI: 1.03–1.39), income (HR: 1.18; 95% CI: 1.01–1.38), or poverty (HR:
1.19; 95% CI: 1.02–1.40), and were not signiﬁcantly
lower in Hispanics (HR: 0.79; 95% CI: 0.53–1.16; 0.80;
95% CI: 0.54 –1.18; and 0.80; 95% CI: 0.54 –1.18, respectively) as compared with Caucasians.
Figure 1 presents the Kaplan–Meier survival curve
for three racial/ethnic groups and the number of cases
at risk. It was clear that the survival was the lowest for
African American patients and the highest for Hispanic, whereas the survival curve for Caucasian patients was between African Americans and Hispanics.
Table 5 also presents the effect of age, Gleason
score, and comorbidity on mortality. The HR of allcause and prostate carcinoma-speciﬁc mortality in-
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TABLE 4
Association between Mortality and SES in Men with Prostate Cancer in 1992–1999
Hazard ratio (95% CI) of mortalitya
SES
(quartile from
high to low)
Education
1st
2nd
3rd
4th
Missing
Poverty
1st
2nd
3rd
4th
Missing
Income
1st
2nd
3rd
4th
Missing
Composite SES
1st
2nd
3rd
4th
Missing

All-cause mortality

Prostate cancer-speciﬁc mortality

Model 1

Model 2

Model 3

Model 4

1.0
1.12 (1.08–1.17)
1.18 (1.14–1.23)
1.27 (1.22–1.32)
1.19 (1.11–1.27)

1.0
1.12 (1.08–1.17)
1.18 (1.13–1.23)
1.26 (1.20–1.31)
1.19 (1.11–1.27)

1.0
1.15 (1.00–1.33)
1.28 (1.11–1.48)
1.43 (1.25–1.65)
1.02 (0.79–1.31)

1.0
1.13 (0.98–1.30)
1.27 (1.11–1.47)
1.39 (1.20–1.61)
0.98 (0.76–1.26)

1.0
1.11 (1.06–1.15)
1.19 (1.14–1.24)
1.28 (1.23–1.34)
1.14 (1.02–1.28)

1.0
1.11 (1.06–1.15)
1.19 (1.14–1.24)
1.28 (1.22–1.34)
1.14 (1.02–1.28)

1.0
1.17 (1.02–1.33)
1.12 (0.97–1.30)
1.36 (1.18–1.55)
1.60 (1.10–2.32)

1.0
1.15 (1.01–1.32)
1.11 (0.96–1.28)
1.31 (1.13–1.52)
1.49 (1.03–2.16)

1.0
1.12 (1.08–1.17)
1.22 (1.17–1.28)
1.28 (1.23–1.34)
1.21 (1.13–1.30)

1.0
1.12 (1.08–1.17)
1.22 (1.17–1.28)
1.28 (1.22–1.34)
1.21 (1.13–1.29)

1.0
1.17 (1.02–1.34)
1.28 (1.11–1.48)
1.43 (1.23–1.67)
1.02 (0.79–1.32)

1.0
1.16 (1.01–1.33)
1.25 (1.08–1.45)
1.37 (1.16–1.61)
0.98 (0.76–1.27)

1.0
1.11 (1.07–1.16)
1.22 (1.17–1.27)
1.31 (1.25–1.36)
1.19 (1.11–1.26)

1.0
1.11 (1.07–1.16)
1.22 (1.17–1.27)
1.31 (1.25–1.37)
1.19 (1.12–1.26)

1.0
1.26 (1.09–1.44)
1.24 (1.07–1.43)
1.48 (1.28–1.70)
1.13 (0.89–1.34)

1.0
1.25 (1.09–1.44)
1.22 (1.05–1.41)
1.40 (1.20–1.64)
1.11 (0.88–1.40)

SES: socioeconomic status; 95% CI: 95% conﬁdence interval; AJCC: American Joint Commission on Cancer; SEER: Surveillance, Epidemiology, and End Results.
a
In models 1 and 3, the hazard ratio is adjusted for age, comorbidity, AJCC stage, Gleason score, year of diagnosis, SEER region, surgery and radiation, hormone, and chemotherapy. Models 2 and 4 are adjusted
for race or ethnicity, in addition to factors in Models 1 and 3.

creased signiﬁcantly with age (P ⬍ 0.001). The HR also
increased with more advanced tumor stage, poorer
grades, and higher comorbidity scores, but the magnitude of the increased risk was much greater for
prostate carcinoma-speciﬁc mortality in association
with Gleason score and AJCC stage, whereas the magnitude of the risk was greater for all-cause mortality in
association with comorbidity.
There was no signiﬁcant interaction between
race/ethnicity and socioeconomic status (education,
income, poverty, and composite socioeconomic status) on the risk of mortality. For example, in every
quartile of educational level there was no signiﬁcant
difference in HR of both all-cause and prostate carcinoma-speciﬁc mortality between African American
and Caucasian men, whereas Hispanic men were signiﬁcantly less likely to die of all causes in the second
and fourth quartiles, but had no signiﬁcantly different
risk of prostate carcinoma-speciﬁc mortality compared with Caucasians.

DISCUSSION
This study examined the disparities in race/ethnicity
and socioeconomic factors in association with survival
among men diagnosed with prostate carcinoma. We
found that in men with local or regional stage prostate
carcinoma, lower socioeconomic status was signiﬁcantly associated with decreased survival, even after
controlling for other patient/tumor characteristics
and treatment. We also found racial/ethnic disparities
in survival, but these disparities reduced substantially
after controlling for socioeconomic factors. Particularly when poverty or income or composite variables
were used as indicators of socioeconomic status, the
risk of all-cause mortality in African American patients
was no longer signiﬁcantly higher than that in Caucasians, indicating that racial/ethnic differences in survival for prostate carcinoma between African American and Caucasian men were largely explained by
socioeconomic status and other factors.
The differences in survival between African
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TABLE 5
Mortality Associated with Race or Ethnicity and SES in Men with Locoregional Prostate Carcinoma
Hazard ratio (95% CI) of mortalitya
All-cause mortality
Race or ethnicity and other factors
Race or ethnicity
Caucasian
African American
Hispanic
Age, yrs
65–69
70–74
75–79
ⱖ 80
AJCC stage
I
II
III
IV
Unknown
Gleason score
2–4
5–7
8–10
Unknown
Comorbidity score
0
1
2
ⱖ3
Composite SES (quartile from high to low)
1st
2nd
3rd
4th
Missing

Prostate cancer-speciﬁc mortality

Model 1

Model 2

Model 3

Model 4

1.00
1.14 (1.09–1.19)
0.85 (0.76–0.94)

1.00
1.01 (0.97–1.06)
0.78 (0.70–0.87)

1.00
1.33 (1.16–1.53)
0.84 (0.57–1.24)

1.00
1.17 (0.99–1.37)
0.78 (0.53–1.16)

1.0
1.24 (1.19–1.29)
1.73 (1.66–1.81)
3.01 (2.88–3.15)

1.0
1.24 (1.19–1.29)
1.73 (1.66–1.81)
2.99 (2.86–3.13)

1.0
1.17 (1.02–1.35)
1.44 (1.25–1.67)
2.41 (2.08–2.79)

1.0
1.17 (1.01–1.34)
1.45 (1.25–1.67)
2.39 (2.07–2.77)

1.0
1.13 (1.08–1.18)
1.21 (1.16–1.27)
1.67 (1.56–1.79)
1.08 (1.04–1.12)

1.0
1.13 (1.08–1.18)
1.21 (1.15–1.27)
1.66 (1.55–1.78)
1.08 (1.05–1.12)

1.0
1.40 (1.19–1.64)
1.93 (1.66–2.24)
3.52 (2.97–4.18)
1.34 (1.18–1.52)

1.0
1.39 (1.18–1.64)
1.92 (1.65–2.23)
3.49 (2.94–4.14)
1.33 (1.18–1.52)

1.0
1.16 (1.11–1.21)
1.73 (1.66–1.82)
1.36 (1.28–1.45)

1.0
1.16 (1.12–1.21)
1.74 (1.66–1.82)
1.36 (1.28–1.44)

1.0
2.47 (2.01–3.05)
8.29 (6.73–10.21)
3.69 (2.86–4.76)

1.0
2.48 (2.01–3.05)
8.28 (6.72–10.20)
3.70 (2.86–4.77)

1.0
1.61 (1.56–1.66)
2.26 (2.17–2.36)
3.49 (3.33–3.66)

1.0
1.60 (1.55–1.65)
2.23 (2.14–2.33)
3.44 (3.28–3.60)

1.0
1.03 (0.93–1.15)
1.18 (1.01–1.38)
1.56 (1.30–1.87)

1.0
1.03 (0.92–1.14)
1.16 (0.99–1.35)
1.53 (1.27–1.84)

—
—
—
—
—

1.0
1.11 (1.07–1.16)
1.22 (1.17–1.27)
1.31 (1.25–1.37)
1.19 (1.12–1.26)

—
—
—
—
—

1.0
1.25 (1.09–1.44)
1.22 (1.05–1.41)
1.40 (1.20–1.64)
1.11 (0.88–1.40)

SES: socioeconomic status; 95% CI: 95% conﬁdence interval; AJCC: American Joint Commission on Cancer.
a
In models 1 and 3, the hazard ratio is adjusted for variables listed in the footnote of Table 4. Models 2 and 4 are adjusted for composite socioeconomic status in addition to above factors.

American and Caucasian patients have been attributed to numerous factors.7–24 A recent study reported that African American patients may be more
likely to seek physicians who provide poorer quality
of care.24 Although racial/ethnic differences are
likely multifactorial, access to quality care and socioeconomic factors are shown to play a major
role.10 –24 Several studies demonstrated that if patients had equal access to quality healthcare, the
outcomes would be similar among different racial
groups.10,15,39 However, other studies showed the
racial disparities still existed even after controlling
for socioeconomic factors and for access to equitable care and treatment.18,22 Our study showed that
among patients who had the same coverage of
Medicare insurance and had same stage (local/re-

gional) prostate carcinoma, African American men
were more likely to present with a higher-grade
cancer. Although the receipt of treatment differed
among racial/ethnic groups, the impact of this factor was minimal in this cohort of cases. However,
differences in mortality between African American
and Caucasian men were substantially reduced (after adjusting for education) or no longer existed
(after adjusting for poverty or income or composite
socioeconomic variable). This indicates that socioeconomic differences are one of the major barriers
to achieving equal outcomes for men with prostate
carcinoma. These socioeconomic differences are
modiﬁable factors that have important implications
in our society. If we make efforts to achieve equal
opportunity for education, employment, and health
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FIGURE 1. Kaplan–Meier survival curve by race/ethnic group (upper curve:
all-cause; bottom curve: prostate carcinoma-speciﬁc).

insurance, the Healthy People 2010⬘s goal40 of eliminating racial disparities in cancer survival is possible.
Our study found that Hispanics had a lower risk of
mortality from prostate carcinoma than did Caucasians and African Americans, even though their socioeconomic status was similar to that of African Americans. This mortality advantage among Hispanics has
often been described as the ‘Hispanic Paradox’ because their low socioeconomic status was a known
determinant of mortality as evidenced in our study,
and because they are also known to have a higher
prevalence of risk factors for mortality. Many studies
explored the reasons for this paradox, including the
‘healthy immigrant theory’ and the factor of strong
social support.41 However, a recent study reported
that the National Death Index may have underestimated mortality for Hispanic men by 9%.41 The small
number of Hispanic subjects in our study may also
have generated some unstable results.
Our study has several strengths. First, it was a
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population-based study, covering all incident cases of
prostate carcinoma in the 11 SEER regions. This large
cohort of patients were pathologically conﬁrmed by
the SEER registries, one of the most authoritative data
sources on cancer. SEER registries also provided reliable information on tumor stage, grade, and longterm followup on vital status.3–5,42 In addition, Medicare claims data enabled us to identify information on
patient comorbidity, which is a strong confounder of
survival. Furthermore, information on chemotherapy
and hormonal therapy can be uniquely identiﬁed from
Medicare claims data.43
This study also has several limitations. First, socioeconomic variables are based on the zip code or
census tract level, and are imperfect proxy measures
of individual level socioeconomic status. Therefore, it
is possible that residual confounding was not properly
controlled in our analyses. One study using the National Longitudinal Mortality Study data showed that
family income and education at the individual level
did not account for much of the excess risk for African
American men with prostate carcinoma compared
with Caucasian men.20
Second, we did not have information on physician
and hospital characteristics, which have also been
shown to be associated with cancer outcomes.24 We
also do not have information on patient or physician
preferences toward treatment such as choice of prostatectomy. The marginal differences in survival between racial/ethnic groups after adjusting for education were likely because of unmeasured factors such
as physician characteristics. Third, we only studied
Medicare beneﬁciary men age ⱖ 65. The results for the
association between race/ethnicity and survival may
not be generalizable to younger patients. However,
most incident cases of prostate carcinoma occur in
older persons,1–5 so the ﬁndings will still be generalizable to a large population. Furthermore, older
persons are often reported to be at higher risk of
underutilization of cancer therapies and are
underrepresented in clinical trials.44 Therefore, targeting this population would have great importance for
much-needed research in identifying health problems
and for improving quality of life. In addition, we examined only patients who had both Medicare Parts A
and B, and were not members of an HMO. The patterns in survival may be different from other cases
excluded.
In conclusion, lower socioeconomic status was
strongly associated with decreased survival in men
with local/regional stage prostate carcinoma. The racial/ethnic disparities in survival in these men were
largely explained by socioeconomic status and other
factors. These ﬁndings have important public health
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implications if we are to achieve the goals of Healthy
People 2010, one of which is to eliminate health disparities among different segments of the population.
Furthermore studies may be needed to address
whether this association is true in younger men with
prostate carcinoma and in subjects diagnosed with
prostate carcinoma in other parts of the world.
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